CPE and breast carcinoma: Previously, CPH was identified as an inhibitor for lysine methyltransferase 7/9 (Set7/9), and a histone lysine methyltransferase (HMT) in breast cancer [13], suggesting that CPH may also serve as an epigenetic modifier.